Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Anidulafungin

FDA-approved product (powder, intravenous), marketed as Eraxis.

Registered studies
43
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Anidulafungin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidemia
  • Candidiasis
  • Peritonitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
FDA pharmacologic class
Echinocandin Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX06; FDA class Echinocandin Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Anidulafungin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Anidulafungin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

    NCT00672841 · start 2008-06

    Registered record
    Registry ID
    NCT00672841
    Conditions
    Invasive Candidiasis
    Interventions
    Preemptive Therapy with Anidulafungin; Empiric antifungal therapy based on physician discretion.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-01
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis
    InterventionPreemptive Therapy with Anidulafungin; Empiric antifungal therapy based on physician discretion.
    PhaseNot applicable
    Registry statusCompleted

  • This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

    NCT00548262 · start 2008-02

    Registered record
    Registry ID
    NCT00548262
    Conditions
    Candidemia; Invasive Candidiasis
    Interventions
    Anidulafungin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-10
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia; Invasive Candidiasis
    InterventionAnidulafungin; Voriconazole
    PhasePhase 4
    Registry statusCompleted

  • Anidulafungin In Treatment Of Candidemia In Asian Subjects

    NCT00537329 · start 2008-01

    Registered record
    Registry ID
    NCT00537329
    Conditions
    Candidemia
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAnidulafungin
    PhasePhase 3
    Registry statusCompleted

  • Anidulafungin PK in Infants and Toddlers

    NCT00734500 · start 2008-01

    Registered record
    Registry ID
    NCT00734500
    Conditions
    Invasive Fungal Infections
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    InterventionAnidulafungin
    PhasePhase 1
    Registry statusCompleted

  • Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

    NCT00496197 · start 2007-07

    Registered record
    Registry ID
    NCT00496197
    Conditions
    Candidiasis
    Interventions
    Eraxis (anidulafungin); Diflucan (fluconazole); Vfend (voriconazole)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-06
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionEraxis (anidulafungin); Diflucan (fluconazole); Vfend (voriconazole)
    PhasePhase 4
    Registry statusCompleted

  • Antimicrobial PK in Infants With Suspected or Confirmed Infection

    NCT00491426 · start 2006-01

    Registered record
    Registry ID
    NCT00491426
    Conditions
    Infection
    Interventions
    Ampicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir; Amphotericin B; Ambisome; Anidulafungin; Caspofungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2010-11
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionAmpicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

    NCT00056381 · start 2003-07

    Registered record
    Registry ID
    NCT00056381
    Conditions
    Neutropenia
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-07
    Completion
    2004-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionAnidulafungin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Anidulafungin in Treating Immunocompromised Children With Neutropenia

    NCT00068471 · start 2003-07

    Registered record
    Registry ID
    NCT00068471
    Conditions
    Infection; Neutropenia; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-07
    Completion
    2007-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Neutropenia; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventionanidulafungin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Anidulafungin Versus Fluconazole in the Treatment of Candidemia

    NCT00058682 · start 2003-04

    Registered record
    Registry ID
    NCT00058682
    Conditions
    Candida; Candidiasis
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-04
    Completion
    2005-01
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandida; Candidiasis
    InterventionAnidulafungin
    PhasePhase 3
    Registry statusCompleted

  • The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

    NCT00056368 · start 2003-03

    Registered record
    Registry ID
    NCT00056368
    Conditions
    Candidiasis
    Interventions
    Anidulafungin; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-03
    Completion
    2004-10
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionAnidulafungin; Fluconazole
    PhasePhase 3
    Registry statusCompleted

  • The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

    NCT00041704 · start 2002-08

    Registered record
    Registry ID
    NCT00041704
    Conditions
    Candidiasis
    Interventions
    Anidulafungin, VER002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-08
    Completion
    2004-08
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionAnidulafungin, VER002
    PhasePhase 2
    Registry statusCompleted

  • A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

    NCT00037206 · start 2002-05

    Registered record
    Registry ID
    NCT00037206
    Conditions
    Aspergillosis
    Interventions
    Anidulafungin, VER002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-05
    Completion
    2003-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    InterventionAnidulafungin, VER002
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

    NCT00037219 · start 2001-08

    Registered record
    Registry ID
    NCT00037219
    Conditions
    Candidiasis
    Interventions
    Anidulafungin, VER002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-08
    Completion
    2002-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionAnidulafungin, VER002
    PhasePhase 2
    Registry statusCompleted